pancreatic cancer | 2 Minute Medicine

A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026

1. An artifical intelligence (AI) model flagged pancreatic cancer in CT scans years before diagnosis, with 2-3x the sensitivity of ...

An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

by2 Minute Medicine

October 25, 2026

0

In a randomized phase 2 trial, camupepimut did not improve disease-free survival versus observation in patients with resected KRAS-mutated pancreatic ...

The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.

Daraxonrasib extends survival in metastatic pancreatic cancer

byDeepti Shroff

September 17, 2026

0

1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...

A variety of pharmaceutical items including a vial, capsule, molecule model, pill blister pack, petri dish with a pipette, and a graph, symbolizing drug development.

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

byDeepti Shroff

September 15, 2026

0

mFlusiva outperforms standard-dose flu vaccine in adults 50 and older The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) ...

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

2 Minute Medicine Rewind July 13, 2026

byPaary Balakumarand1 others

July 13, 2026

0

Evaluating the effectiveness of bilateral erector spinae plane blocks in addition to standard multimodal analgesia at reducing opioid consumption in ...

New targeted therapy daraxonrasib improves survival in pancreatic cancer

byDeepti Shroff

May 5, 2026

0

1. Daraxonrasib significantly improves survival in metastatic pancreatic cancer compared with standard chemotherapy. 2. Strong response rates in combination therapy ...

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

byDeepti Shroff

May 4, 2026

0

Geopolitical instability in the Strait of Hormuz threatens global generic drug supply Ongoing escalations in the Strait of Hormuz have ...

Obesity treatment collage: a bathroom scale with a blank dial, a coiled tape measure and a bowl of fresh vegetables

GLP-1 receptor agonists show little effect on obesity-related cancer risk

byAdrian Wongand1 others

December 8, 2025

0

1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant ...

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial

bySimon Panand1 others

August 7, 2025

0

1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin ...